Novartis announced today the early termination of the ALTITUDE trial, which was testing the effect of the direct renin inhibitor aliskiren (Rasilez, Tekturna) in type2diabetics at high risk for cardiovascular and renal events.
The study, which examined insurance records for more than 2, 500 diabetics between February 2005 and December 2008, found that patients hospitalized with pancreatitis were twice as likely to be taking one of these drugs, as opposed to a control group of Type2diabetics who did not have pancreatitis.